Endocrine Abstracts

Purpose: Obesity is a chronic disease with a high risk of cardiovascular and metabolic comorbidities, hence a decrease > 5-10% of the initial body weight (BW) is essential to achieve improvement of cardiometabolic dysfunction. Bariatric surgery currently represents a valid therapeutic option in this clinical setting, especially in patients unresponsive to a dietary-nutritional approach. Obesity instigates adaptive hormone changes, yet the role of baseline hormone setting o...

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common cause of chronic liver disease and is the leading cause of liver-related morbidity and mortality. MASLD is rapidly becoming a major aetiology for the development of hepatocellular carcinoma (HCC), the most common liver cancer. As the incidence of MASLD continues to rise, it is crucial to understand the molecular alterations that lead to HCC. Previous studies have revealed a significant alterati...

Identifying effective strategies and underneath molecular signatures is crucial to combat certain metabolic diseases with increasing incidence such as obesity and MASLD (metabolic dysfunction-associated steatotic liver disease). The hepatic secretome plays a crucial role at controlling global energy metabolism and inflammation in MASLD. However, the interplay between diet composition and the eating architecture on the dynamic response of secretome as a tool to improve disease ...

Brown adipose tissue (BAT) may directly dissipate energy into heat and is associlated with a metabolically favorable phenotype. Cold exposure activates BAT via the sympathetic nervous system and its transmitter norepinephrine. In rodents, the activation is facilitated by the β3-adrenoreceptor (β3-AR). In humans treatment with the β3-AR agonist mirabegon leads to a rather weak activation of BAT as compared to a cold stimulus. In vitro studies in cell lines from h...

Background and Aims: Our objective was to assess the association between genetic polymorphisms in TCF7L2, CTRB1/2 and GLP-1R genes and inter-individual variability in response to treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in terms of glycemic control and weight loss among Greek individuals with type 2 diabetes mellitus (T2DM) and to identify potential predictors of response to GLP-1 RA therapy.Material...